secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-08-11T11:33:42+00:00
Accession:  0001730463-26-000119
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus Q2 revenue up 119% to $45.7M; FY26 guidance raised to $140-150M
-----------------------------------------------------------------------

- Q2 2026 net product revenue $45.7M vs $20.9M YoY (+119%); Q1 2026 was $26.2M.
- Gross margin jumped to 55% in Q2 from 6% in Q1 2026 on higher volumes and cost cuts.
- Net loss narrowed to $39.1M ($0.15/sh) from $47.9M ($0.18/sh) in Q2 2025.
- Closed $75M tranche of up to $250M five-year interest-only Perceptive Advisors credit facility.
- Workforce reduction ~13% to save ~$15M annual opex; cash $201.6M at June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/0001730463-26-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autl-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer